That said, to evaluate glucagon’s impact on, for example, glucose production in individuals with and without hepatic steatosis, the manipulation of the glucagon/insulin ratio by somatostatin-induced pancreas clamps and continuous infusion of insulin and glucagon may be a tool to investigate glucagon resistance [241]. This evidence concerns the gene INS and fatty liver disease.